

Electronic Acknowledgement Receipt

| | |
|---|--|
| EFS ID: | 3913654 |
| Application Number: | 10601171 |
| International Application Number: | |
| Confirmation Number: | 4940 |
| Title of Invention: | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
| First Named Inventor/Applicant Name: | Gerald W. Fischer |
| Customer Number: | 00959 |
| Filer: | Alissa Heather Faris |
| Filer Authorized By: | |
| Attorney Docket Number: | 103901-4197 |
| Receipt Date: | 09-SEP-2008 |
| Filing Date: | 23-JUN-2003 |
| Time Stamp: | 17:44:08 |
| Application Type: | Utility under 35 USC 111(a) |

Payment information:

| | |
|--|-----------------|
| Submitted with Payment | yes |
| Payment Type | Deposit Account |
| Payment was successfully received in RAM | \$1230 |
| RAM confirmation Number | 3025 |
| Deposit Account | 120080 |
| Authorized User | |

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

| Document Number | Document Description | File Name | File Size(Bytes)/Message Digest | Multi Part /.zip | Pages (if appl.) |
|-----------------|--|-----------|--|------------------|------------------|
| 1 | Applicant Arguments/Remarks Made in an Amendment | REPLY.pdf | 233538 b2cfcae39cdfe018e76dc8bbf7d88e0263a8 bdb2 | no | 22 |

Warnings:

Information:

| | | | | | |
|---|--|---------------|---|----|---|
| 2 | Applicant Arguments/Remarks Made in an Amendment | AppendixE.pdf | 1042505 07cc70bf90ec145d28ddba59389ce571e1a a43ab | no | 2 |
|---|--|---------------|---|----|---|

Warnings:

Information:

| | | | | | |
|---|--|---------------|---|----|---|
| 3 | Applicant Arguments/Remarks Made in an Amendment | AppendixF.pdf | 679616 577b9bd28a72c4635a48beec6ed0f00587 51c8b | no | 2 |
|---|--|---------------|---|----|---|

Warnings:

Information:

| | | | | | |
|---|--|--------------------------|---|----|----|
| 4 | Applicant Arguments/Remarks Made in an Amendment | AppendixG_Henckaerts.pdf | 2819231 07fec99da8d644b1f0b5b8636646a157453 3889b | no | 10 |
|---|--|--------------------------|---|----|----|

Warnings:

Information:

| | | | | | |
|---|--|--------------------------------|---|----|---|
| 5 | Applicant Arguments/Remarks Made in an Amendment | AppendixH_Clark_and_Easmon.pdf | 1364422 f7d32d3c10ef1b4e89143b5610a840c0208 e24c1 | no | 5 |
|---|--|--------------------------------|---|----|---|

Warnings:

Information:

| | | | | | |
|---|--|---------------------|---|----|----|
| 6 | Applicant Arguments/Remarks Made in an Amendment | AppendixI_Seder.pdf | 4677327 a0db10d3b45b3375b878e3c5e6a28154a0 8af12c | no | 12 |
|---|--|---------------------|---|----|----|

Warnings:

Information:

| | | | | | |
|---|---|--------------------------------------|---|----|---|
| 7 | Information Disclosure Statement Letter | Information_Disclosure_Statement.pdf | 28089 909668444e7dfb45e04bf3e4ba014ef64907 4ea7 | no | 2 |
|---|---|--------------------------------------|---|----|---|

Warnings:

Information:

| | | | | | |
|---|--|----------|---|----|---|
| 8 | Information Disclosure Statement (IDS) Filed (SB/08) | SB08.pdf | 35416 f714a1d755e6982608bd035228386e3235c 10a54 | no | 1 |
|---|--|----------|---|----|---|

Warnings:**Information:**

This is not an USPTO supplied IDS fillable form

| | | | | | |
|---|---------------|--|--|----|---|
| 9 | NPL Documents | Drabick-A_Monoclonal_antibody_direct.pdf | 170897 6350fd65f1563c2bb3d597cac37b3d3130b 14889 | no | 1 |
|---|---------------|--|--|----|---|

Warnings:**Information:**

| | | | | | |
|----|---------------|---------------------------------|---|----|---|
| 10 | NPL Documents | Winter-Humanized_Antibodies.pdf | 396913 7baa0fa868b427fb21e173e37dcbe117ba a17ae | no | 4 |
|----|---------------|---------------------------------|---|----|---|

Warnings:**Information:**

| | | | | | |
|----|-------------------|-----------------------|---|----|---|
| 11 | Extension of Time | Extension_of_Time.pdf | 31281 49d5b891482575434633df99205ea54ddb d323b5 | no | 1 |
|----|-------------------|-----------------------|---|----|---|

Warnings:**Information:**

| | | | | | |
|----|------------------------|--------------|---|----|---|
| 12 | Fee Worksheet (PTO-06) | fee-info.pdf | 31888 0c353f9fb169fa052b6c094a908c64c07074 ce11 | no | 2 |
|----|------------------------|--------------|---|----|---|

Warnings:**Information:**

| | |
|-------------------------------------|----------|
| Total Files Size (in bytes): | 11511123 |
|-------------------------------------|----------|

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.